CRN SWP Business Intelligence Unit Name of report: Cancer Update Q2 2017/2018 31 st October 2017 Release date: Data source(s) used: Portfolio ODP Data cut-off: 30th October 2017 Brief Summary: Summary of recruitment activity to cancer sub specialty group portfolios nationally and regionally for Q2 of 2017/2018
National Urology Group Recruitment 100000 90000 87234 77763 80000 76411 69072 70000 61310 59852 60000 55093 51878 49011 50000 40000 31418 30000 20000 14360 10650 10361 9965 8243 10000 7136 7165 6882 5652 5075 0 2008/09 2009/10 2010/11 2011/12 2012/13 2013/14 2014/15 2015/16 2016/17 2017/18 Cancer Urology Data from Portfolio ODP – cut off 30 th October 2017 Data from Portfolio ODP – cut off 17 th July 2017 Clinical Research Network
SWP Urology Group Recruitment 2500 2038 2012 1960 2000 1823 1797 1612 1559 1549 1500 1200 1000 930 665 490 452 500 354 254 243 230 224 185 147 0 2008/09 2009/10 2010/11 2011/12 2012/13 2013/14 2014/15 2015/16 2016/17 2017/18 Cancer Urology Data from Portfolio ODP – cut off 30 th October 2017 Data from Portfolio ODP – cut off 17 th July 2017 Clinical Research Network
Urology Group National Perspective 2000 1800 1600 1400 1200 1000 800 600 400 200 0 2015/16 2016/17 2017/18 Data from Portfolio ODP – cut off 30 th October 2017 Data from Portfolio ODP – cut off 17 th July 2017 Clinical Research Network
Urology Group National Perspective 2016/2017 2017/2018 CRN Adj. for Pop. Adj. for Pop. Recruitment Rank Recruitment Rank Rank Rank East Midlands 572 13 14 301 8 11 Eastern 941 7 10 287 9 10 Greater Manchester 1845 1 1 523 3 1 Kent, Surrey and Sussex 1538 2 4 605 2 2 North East and North Cumbria 1234 4 3 357 7 5 North Thames 1458 3 9 641 1 6 North West Coast 319 15 15 89 15 15 North West London 843 9 2 128 13 13 South London 1039 6 5 417 5 3 South West Peninsula 665 12 7 243 11 7 Thames Valley and South Midlands 699 11 6 280 10 4 Wessex 800 10 8 237 12 9 West Midlands 847 8 12 366 6 12 West of England 354 14 13 104 14 14 Yorkshire and Humber 1206 5 11 497 4 8 Data from Portfolio ODP – cut off 30 th October 2017 Data from Portfolio ODP – cut off 17 th July 2017 Clinical Research Network
Urology Group SWP Recruitment Northern Devon Healthcare NHS Trust Plymouth Hospitals NHS Trust Royal Cornwall Hospitals NHS Trust Royal Devon and Exeter NHS Foundation Trust Taunton and Somerset NHS Foundation Trust Torbay and South Devon NHS Foundation Trust 2015/16 2016/17 Yeovil District Hospital NHS Foundation Trust 2017/18 NHS Kernow CCG NHS NEW Devon CCG NHS Somerset CCG NHS South Devon and Torbay CCG Non-NHS Activity in South West Peninsula 0 50 100 150 200 Data from Portfolio ODP – cut off 30 th October 2017 Data from Portfolio ODP – cut off 17 th July 2017 Clinical Research Network
Key Trials • Prostate – Add Aspirin (any prostate RT pt or post prostatectomy pt) – PIVOTAL BOOST (HDR vs IMRT boost to prostate tumour and/ or hypofactionated pelvic RT) – STAMPEDE • Bladder – RAIDER (adaptive bladder radiotherapy +/- tumour boost) – ATLANTIS (all sites to consider opening; STAMPEDE like maintenance study following response after first line platinum based palliative chemotherapy) • Renal – RAMPART (adjuvant single or combination immunotherapy post nephrectomy in patients with intermediate or high risk RCC). 7 Data from Portfolio ODP – cut off 17 th July 2017 Clinical Research Network
The Future • Continue to refer to Urology portfolio maps in MDT to facilitate network referrals • https://sites.google.com/a/nihr.ac.uk/crn-south-west- peninsula/business-intelligence-unit-1/cancer-portfolio- maps/urology-portfolio • Immunotherapy studies being considered within the UK for high risk non-muscle invasive bladder cancers – Important to have this within the network – Need to consider how this group of patients will be managed, as will need to be seen by oncology • All MDT members invited to the Network bladder cancer study day 26/01/2017 Exeter ‘ Embracing a multidisciplinary and evidence based approach’ 8 Data from Portfolio ODP – cut off 17 th July 2017 Clinical Research Network
Recommend
More recommend
